Bogdana Suchorska

List of Publications by Year
in descending order

30 papers	1,869 citations	18 h-index (430874)
28 g-index (501196)		
30 all docs	30 docs citations	30 times ranked
1982 citing authors		

#	Article	IF	Citations
1	Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma. , 2022, , 125-128.		0
2	PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging. Frontiers in Oncology, 2021, 11, 646387.	2.8	35
3	Use of PET Imaging in Neuro-Oncological Surgery. Cancers, 2021, 13, 2093.	3.7	23
4	TERT-Promoter Mutational Status in Glioblastoma â€" Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. Frontiers in Oncology, 2021, 11, 645316.	2.8	4
5	PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. Journal of Neuro-Oncology, 2021, 153, 283-291.	2.9	13
6	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. Cancers, 2021, 13, 3163.	3.7	5
7	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 4415-4425.	6.4	29
8	L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas. EJNMMI Research, 2021, 11, 124.	2.5	13
9	Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 2581-2589.	6.4	34
10	Comment on â€œHypometabolic gliomas on FET-PETâ€"is there an inverted U-curve for survival?â€. Neuro-Oncology, 2019, 21, 1612-1613.	1.2	9
11	PATH-04. INFLUENCE OF INDIVIDUAL CpG METHYLATION STATUS OF THE MGMT PROMOTOR ON OUTCOME IN ADULT PATIENTS WITH GLIOBLASTOMA MULTIFORME RECEIVING ALKYLATING AGENT TREATMENT. Neuro-Oncology, 2019, 21, vi143-vi143.	1.2	0
12	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. European Journal of Cancer, 2019, 107, 15-27.	2.8	30
13	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology, 2018, 20, 279-288.	1.2	71
14	Role of amino-tracer PET for decision-making in neuro-oncology. Current Opinion in Neurology, 2018, 31, 720-726.	3.6	8
15	Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation. EJNMMI Research, 2018, 8, 91.	2.5	20
16	The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2018, 62, 267-271.	0.7	12
17	18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. Journal of Neuro-Oncology, 2018, 139, 721-730.	2.9	28
18	O-(2-[18F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres. EJNMMI Research, 2017, 7, 64.	2.5	14

#	Article	IF	Citations
19	Serial ^{18}F-FET PET Imaging of Primarily ^{18}F-FET–Negative Glioma: Does It Make Sense?. Journal of Nuclear Medicine, 2016, 57, 1177-1182.	5.0	56
20	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology, 2016, 18, 1199-1208.	1.2	566
21	Usefulness of PET Imaging to Guide Treatment Options in Gliomas. Current Treatment Options in Neurology, 2016, 18, 4.	1.8	16
22	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial. Neuro-Oncology, 2016, 18, 549-556.	1.2	187
23	Biological tumor volume in [18] FET-PET before radiochemotherapy correlates with survival in GBM. Neurology, 2015, 84, 710-719.	1.1	144
24	Prognostic Significance of Dynamic ^{18}F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. Journal of Nuclear Medicine, 2015, 56, 9-15.	5.0	144
25	PET imaging for brain tumor diagnostics. Current Opinion in Neurology, 2014, 27, 683-688.	3.6	32
26	Dynamic ^{18}F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. Journal of Nuclear Medicine, 2014, 55, 198-203.	5.0	123
27	[[18] F]Fluoroethyltyrosine–Positron Emission Tomography-Based Therapy Monitoring after Stereotactic Iodine-125 Brachytherapy in Patients with Recurrent High-Grade Glioma. Molecular Imaging, 2013, 12, 7290.2012.00027.	1.4	36
28	[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma. Molecular Imaging, 2013, 12, 137-47.	1.4	24
29	MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1021-1029.	6.4	160
30	Stereotactic brachytherapy of low-grade cerebral glioma after tumor resection. Neuro-Oncology, 2011, 13, 1133-1142.	1.2	33